Ancillary Study: Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (LA CAB) for the Prevention of HIV among Adolescents
What is HPTN 084-01?
HPTN 084-01 (The LIFT Study) is a clinical trial examining whether injectable cabotegravir (CAB) for PrEP (pre-exposure prophylaxis) is safe and acceptable for adolescent females (assigned female at birth).
Who is participating in HPTN 084-01?
This study will be enrolling about 50 adolescent females (assigned female at birth) under the age of 18 at sites in South Africa, Uganda, and Zimbabwe.
Why is HPTN 084-01 important?
Adolescents and young adults make up a large number of new HIV infections worldwide. Although taking a daily pill for PrEP works to protect people from HIV, having to take a daily pill has proven to be difficult for some people. Long-acting injectable PrEP has the potential to protect people from HIV without having to take a daily pill.
What will happen during HPTN 084-01?
Participants will move through the study in 3 steps:
Step 1: Participants will take one CAB pill every day for five weeks
Step 2: Participants will receive a total of 5 CAB injections over 6 months
Step 3: Participants will come to the clinic for study visits quarterly and receive Truvada for PrEP for about one year.
- HPTN 084-01 Protocol Version 1.0
- HPTN 084-01 LoA #1 to Protocol V1.0
- HPTN 084-01 LoA #2 to Protocol V1.0
- HPTN 084-01 CM #1 to LoA #1 to Protocol V1.0
- The Similarities and Differences Between HPTN 083-01 and HPTN 084-01 - August 2020
- The Similarities and Differences Between HPTN 084 and HPTN 084-01 - August 2020
- The Similarities and Differences Between The Parent Studies and Twins Studies - August 2020
More Study Documents
You must request access to private documents (i.e. call summaries) from the study team. Please email Jen Womack at email@example.com for access to these documents.
To establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people.
A Phase IIB single arm, open label safety, tolerability, and acceptability study
Sexually-active, healthy female adolescents aged below 18 years.
Participant recruitment will take approximately 12 months. Oral study product will be administered for 5 weeks, followed by 34 weeks on injectable product then quarterly visits for 48 weeks after final injection. All participants who have received at least one injection will be followed for 48 weeks after their last injection. Waning levels of cabotegravir (the PK tail) will be covered with locally sourced oral TENOFOVIR/EMTRICITABINE (TRADE NAME: TDF/FTC, TRUVADA®) for daily use for 48 weeks. Total study duration per participant will be approximately 21 months.
Step 1 – oral cabotegravir (30mg tablet); Step 2 – injectable cabotegravir 3 mL (600 mg) intramuscular (IM) injection; Step 3 – TENOFOVIR/EMTRICITABINE (TRADE NAME: TDF/FTC, TRUVADA®) (300mg/200mg tablet)
To evaluate the safety, tolerability and acceptability of CAB LA in healthy HIV-uninfected female adolescents aged below 18 years.
To examine adherence to and timeliness of injections over time among adolescent participants provided CAB LA and information regarding its safety and unknown efficacy.
To examine patterns of sexual risk behavior over time among adolescent participants provided CAB LA and information regarding its safety and unknown efficacy.
To evaluate the safety of CAB LA for up to 48 weeks of follow-up after final injection.
To characterize the pharmacokinetics of CAB LA.